A Phase 4 interventional study of Spironolactone and Placebo in Mild Cognitive Impairment and Alzheimer Disease, sponsored by Emory University. Completed at 1 site in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by Emory University · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Cognitive Dysfunction by Emory University — 6 open to participants now, 6 under way, none of them phase 3. Cognitive Dysfunction · Emory University.
Among the 24 studies in Cognitive Dysfunction by Emory University, this one is the 17th largest by enrollment of the 19 interventional ones that give a count, is the only one that started in 2022, is one of 3 in phase 4, and was the 15th registered.
3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.
Browse Cognitive Dysfunction studies →6 of the 24 studies in Cognitive Dysfunction by Emory University are open now, in 1 country. Recruiting first, the newest first:
Emory University · Sites in United States
Ages 18+ · Healthy volunteers
Emory University · Sites in United States
Ages 50–85
Emory University · Sites in United States
Ages 50–90
Emory University · Sites in United States
Ages 55+
Emory University · Sites in United States
Ages 50–90
By country, each count listing its studies:
Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 27 is below the median of 64 across 2,804 interventional studies indexed under Cognitive Dysfunction.
Median enrollment 45 across the 19 interventional studies, 234 across the 5 observational. Of the 18 that completed or were terminated, 7 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
Emory University is the lead sponsor of 1,406 studies on the registry; 224 are open to participants now.
Of its 238 completed or terminated interventional studies of FDA-regulated products, 179 (75%) have results posted.
2 of the studies in Cognitive Dysfunction by Emory University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06484244Emory UniversityLocomotion Adaptation Deficits in Older Adults With Mild Cognitive Impairment and Alzheimers Disease | 2026-12-31 |
| NCT07296133Emory UniversityGAMES Intervention in MCI (Mild Cognitive Impairment) | 2027-03 |
Add all 2 to your calendar (.ics) → With an account.
Among the 24 studies in Cognitive Dysfunction by Emory University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate whether a blood pressure medication, spironolactone, can be tolerated by older African American adults that have memory and thinking problems, also called mild cognitive impairment (MCI). This study will also investigate the effect of spironolactone on memory and thinking abilities as measured by performance on cognitive tests, which are tests that measure memory and thinking skills. Participants will take spironolactone or a placebo for one year and will have 4 to 5 study visits during the study period.
In 2018, 5.5 million older adults in the United States were diagnosed with Alzheimer's disease, and it is predicted that 15 million people will be diagnosed with dementia, including Alzheimer's disease by 2060. Older African Americans adults are more likely to be diagnosed with Alzheimer's disease as compared to Whites. Research search studies on high blood pressure show that African Americans have higher levels of the hormone aldosterone that can be involved with regulation of blood pressure and blood vessels. Research studies also show that changes in blood vessels in the brain from higher aldosterone levels are related to changes in thinking skills and memory (cognition). Spironolactone is a drug that blocks aldosterone and has been used to treat high blood pressure for 60 years. More recently, this drug has shown to have the potential to decrease declines in thinking skills and memory.
Spironolactone is widely used in clinical practice and is well-tolerated by younger and older persons. As such, this study is designed to learn how a small group of older African American adults with mild cognitive impairment will tolerate the drug. Persons who are eligible for the study and agree to participate will receive spironolactone or a placebo and be monitored for drug side effects for one year.
During the study, the researchers will monitor changes in thinking and memory and blood vessel stiffness, in addition to side effects that may be related to the drug. Study tests include questionnaires that evaluate thinking skills and memory, and an ultrasound that measures the stiffness of blood vessels in the neck which deliver blood to the brain. The thinking and memory tests and ultrasound will be performed at the beginning of the study, then repeated at the end of the study.
The results of this study can justify a larger size study of spironolactone in older African Americans with mild cognitive impairment. The study has the potential to identify a new use for a well-known drug that is safe and widely used in current clinical practice. Further, the results from this study can address a racial difference in Alzheimer's disease and preserve the health of the brain as people age.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Blood pressure (BP) and hypertension criteria: normotensive and hypertensive participants will be eligible
MCI defined as:
Abnormal memory function per the Logical Memory subscale (Delayed Paragraph Recall, Paragraph A only) from the Wechsler Memory Scale-Revised (the maximum score is 25):
Exclusion Criteria:
Hypertension
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with mild cognitive impairment or early Alzheimer's Disease who are randomized to receive spironolactone for 12 months.
Drug: Spironolactone
Participants with mild cognitive impairment or early Alzheimer's Disease who are randomized to receive a placebo to match spironolactone for 12 months.
Drug: Placebo
Study participants will receive a 25 mg dose of spironolactone. Participants will take one capsule by mouth per day for 12 months.
Also known as: Aldactone
A placebo to match spironolactone will be taken orally once per day for 12 months.
Count of Adverse Events
The safely of the study treatment is assessed with the total number of adverse events experienced in each study arm.
Time frame: Month 12
Number of Participants Not Completing The Study
The tolerability of the study treatment is assessed by participant attrition in each study arm. The number of participants who left the study prior to completing the 12 month study.
Time frame: Month 12
Change From Baseline in Trail Making Test Part A Score
In Part A of the Trail Making Test (TMT) participants are presented with a sheet of paper with 25 circles numbered 1 through 25. Participants are asked to draw lines connecting the circles in ascending order of the numbers. The task is scored as the amount of time it takes in seconds for the circles to be correctly connected. The average time to complete the task is 29 seconds. Times greater than 78 seconds indicate cognitive impairment. The change from baseline is a positive number when the Month 12 score is lower than the baseline score, indicating fewer seconds spent to complete the task at the follow-up time point.
Time frame: Baseline, Month 12
Change From Baseline in Trail Making Test Part B Score
Part B of the Trail Making Test (TMT) includes a sheet of paper with circles with numbers (1-13) and letters (A-L). Participants are asked to draw lines connecting the circles in ascending order of the numbers and letters, alternating between numbers and letters. The task is scored as the amount of time it takes in seconds for the circles to be correctly connected. The average time to complete the task is 75 seconds. Times greater than 273 seconds indicate cognitive impairment. The change from baseline is a positive number when the Month 12 score is lower than the baseline score, indicating fewer seconds spent to complete the task at the follow-up time point.
Time frame: Baseline, Month 12
Change in From Baseline in Rey Auditory and Verbal Learning (RAVLT) Test Delayed Recall Score
The RAVLT test is a 15-item neuropsychological measure of attention, concentration, verbal learning, and memory. Total scores range from 0 to 15, where higher scores indicate better recall. The change from baseline is a negative number when the Month 12 score is higher than the baseline score, indicating better recall at the follow-up time point.
Time frame: Baseline, Month 12
Change From Baseline in Number Span Forward Test Score
The Number Span is a brief test that assesses immediate memory and attention. Participants are asked to repeat strings of numbers forwards. The score is the number of digits that are repeated correctly. Higher scores indicate improved memory and attention. The change from baseline is a negative number when the Month 12 value is higher than the baseline value, indicating more numbers repeated correctly at the follow-up time point.
Time frame: Baseline, Month 12
Change From Baseline in Number Span Backward Test Score
The Number Span is a brief test that assesses immediate memory and attention. Participants are asked to repeat strings of numbers backward. The score is the number of digits that are repeated correctly. Higher scores indicate improved memory and attention. The change from baseline is a negative number when the Month 12 value is higher than the baseline value, indicating more numbers repeated correctly at the follow-up time point.
Time frame: Baseline, Month 12
Participant enrollment began September 6, 2022 and follow-up assessments for the Month 12 time point were completed by September 23, 2025.
| Milestone | Spironolactone | Placebo |
|---|---|---|
| Started | 13 | 14 |
| Completed | 11 | 14 |
| Not completed | 2 | 0 |
| Withdrew: Withdrawal by subject | 2 | 0 |
The safely of the study treatment is assessed with the total number of adverse events experienced in each study arm.
| adverse events | Spironolactone | Placebo |
|---|---|---|
| Count of Adverse Events | 24 | 27 |
The tolerability of the study treatment is assessed by participant attrition in each study arm. The number of participants who left the study prior to completing the 12 month study.
| Participants | Spironolactone | Placebo |
|---|---|---|
| Number of Participants Not Completing The Study | 2 | 0 |
In Part A of the Trail Making Test (TMT) participants are presented with a sheet of paper with 25 circles numbered 1 through 25. Participants are asked to draw lines connecting the circles in ascending order of the numbers. The task is scored as the amount of time it takes in seconds for the circles to be correctly connected. The average time to complete the task is 29 seconds. Times greater than 78 seconds indicate cognitive impairment. The change from baseline is a positive number when the Month 12 score is lower than the baseline score, indicating fewer seconds spent to complete the task at the follow-up time point.
| seconds | Spironolactone | Placebo |
|---|---|---|
| Change From Baseline in Trail Making Test Part A Score | -17.2 ± 18.5 | 0.36 ± 43.2 |
Part B of the Trail Making Test (TMT) includes a sheet of paper with circles with numbers (1-13) and letters (A-L). Participants are asked to draw lines connecting the circles in ascending order of the numbers and letters, alternating between numbers and letters. The task is scored as the amount of time it takes in seconds for the circles to be correctly connected. The average time to complete the task is 75 seconds. Times greater than 273 seconds indicate cognitive impairment. The change from baseline is a positive number when the Month 12 score is lower than the baseline score, indicating fewer seconds spent to complete the task at the follow-up time point.
| seconds | Spironolactone | Placebo |
|---|---|---|
| Change From Baseline in Trail Making Test Part B Score | -17.9 ± 65.9 | -13.7 ± 100.0 |
The RAVLT test is a 15-item neuropsychological measure of attention, concentration, verbal learning, and memory. Total scores range from 0 to 15, where higher scores indicate better recall. The change from baseline is a negative number when the Month 12 score is higher than the baseline score, indicating better recall at the follow-up time point.
| score on a scale | Spironolactone | Placebo |
|---|---|---|
| Change in From Baseline in Rey Auditory and Verbal Learning (RAVLT) Test Delayed Recall Score | -2.31 ± 4.07 | 0.71 ± 4.81 |
The Number Span is a brief test that assesses immediate memory and attention. Participants are asked to repeat strings of numbers forwards. The score is the number of digits that are repeated correctly. Higher scores indicate improved memory and attention. The change from baseline is a negative number when the Month 12 value is higher than the baseline value, indicating more numbers repeated correctly at the follow-up time point.
| digits repeated correctly | Spironolactone | Placebo |
|---|---|---|
| Change From Baseline in Number Span Forward Test Score | -1.08 ± 3.33 | -0.50 ± 4.62 |
The Number Span is a brief test that assesses immediate memory and attention. Participants are asked to repeat strings of numbers backward. The score is the number of digits that are repeated correctly. Higher scores indicate improved memory and attention. The change from baseline is a negative number when the Month 12 value is higher than the baseline value, indicating more numbers repeated correctly at the follow-up time point.
| digits repeated correctly | Spironolactone | Placebo |
|---|---|---|
| Change From Baseline in Number Span Backward Test Score | -1.00 ± 3.11 | -0.43 ± 2.47 |
Collected over Information on adverse events was collected from the time participants initiated the study treatment and continued through the final assessment (up to 12 months).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Spironolactone | 0/13 (0%) | 0/13 (0%) | 13/13 (100%) |
| Placebo | 0/14 (0%) | 1/14 (7.1%) | 14/14 (100%) |
| Event | Spironolactone | Placebo |
|---|---|---|
| Asthma exacerbationRespiratory, thoracic and mediastinal disorders | 0/13 | 1/14 |
| Event | Spironolactone | Placebo |
|---|---|---|
| DizzinessGeneral disorders | 3/13 | 1/14 |
| FatigueGeneral disorders | 3/13 | 2/14 |
| LightheadednessGeneral disorders | 3/13 | 2/14 |
| WeaknessGeneral disorders | 0/13 | 3/14 |
| Allergic reaction of unknown causeImmune system disorders | 2/13 | 0/14 |
| Low blood pressureVascular disorders | 2/13 | 1/14 |
| ConstipationGastrointestinal disorders | 0/13 | 2/14 |
| Muscle crampsMusculoskeletal and connective tissue disorders | 0/13 | 2/14 |
| Absence seizureNervous system disorders | 1/13 | 0/14 |
| Coronavirus 2019 (COVID-19) infectionInfections and infestations | 1/13 | 1/14 |
| Age, Continuous(years) | Spironolactone | Placebo | Total |
|---|---|---|---|
| Mean | 69.2 ± 4.71 | 72.2 ± 7.65 | 71.0 ± 6.54 |
| Sex: Female, Male(Participants) | Spironolactone | Placebo | Total |
|---|---|---|---|
| Female | 4 | 12 | 16 |
| Male | 9 | 2 | 11 |
| Race and Ethnicity Not Collected(Participants) | Spironolactone | Placebo | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Region of Enrollment(Participants) | Spironolactone | Placebo | Total |
|---|---|---|---|
| United States | 13 | 14 | 27 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — All of the individual participant data collected during the trial, after deidentification, will be shared.
Supporting information: Study protocol
Time frame: The data will become available beginning 36 months and ending three years following article publication.
Access criteria: The data will be shared with researchers who provide a methodically sound proposal in order to achieve aims in the approved proposal. Proposals may be submitted up to 36 months following article publication. After 36 months, the data will be available in Emory University's data warehouse but without investigator support other than deposited metadata. Proposals should be directed to antoine.trammell@emory.edu. The requestors will need to sign a data access agreement to gain access to the data.
Ran from Sep 2022 to primary completion in Sep 2025, 36 months.
Results were first posted in Nov 2026, 1 year 1 month after primary completion. A results delay was requested in Sep 2026.
Of 43 non-industry phase 4 interventional studies under Cognitive Dysfunction, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 69. This study's 36 months is below that.
Counting every sponsor, half of 51 studies reached it within 54 months; a quarter within 20 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Spironolactone